Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $25.75

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) have received a consensus rating of “Buy” from the six research firms that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $25.75.

Several analysts recently issued reports on VERV shares. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Guggenheim upped their target price on Verve Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, April 15th. Royal Bank of Canada cut their target price on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. Canaccord Genuity Group upped their target price on Verve Therapeutics from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, April 15th. Finally, HC Wainwright upped their target price on Verve Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, April 14th.

Hedge Funds Weigh In On Verve Therapeutics

A number of institutional investors have recently modified their holdings of the business. Woodline Partners LP acquired a new position in shares of Verve Therapeutics during the 1st quarter worth $12,648,000. Goldman Sachs Group Inc. raised its holdings in shares of Verve Therapeutics by 90.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,413,118 shares of the company’s stock worth $6,458,000 after buying an additional 671,939 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Verve Therapeutics by 1,028.7% during the 1st quarter. AQR Capital Management LLC now owns 373,207 shares of the company’s stock worth $1,706,000 after buying an additional 340,143 shares in the last quarter. Alpine Global Management LLC acquired a new position in shares of Verve Therapeutics during the 1st quarter worth $57,000. Finally, Ieq Capital LLC acquired a new position in shares of Verve Therapeutics during the 1st quarter worth $316,000. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Price Performance

VERV opened at $4.63 on Wednesday. The business has a fifty day simple moving average of $4.78 and a 200 day simple moving average of $5.86. The company has a market capitalization of $412.73 million, a PE ratio of -1.88 and a beta of 1.82. Verve Therapeutics has a 1 year low of $2.86 and a 1 year high of $9.31.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. The business had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities analysts anticipate that Verve Therapeutics will post -2.49 earnings per share for the current fiscal year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.